TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Canhão, Helena ^a,b,c   Rodrigues, Ana Maria ^a,b   Santos, Maria José ^a,d   Carmona Fernandes, Diana ^a   Bettencourt, Bruno F ^e,f   Cui, Jing ^c   Rocha, Fabiana L ^e,f   Canas Silva, José ^d   Polido Pereira, Joaquim ^a,b   Pereira Silva, José Alberto ^b   Costa, José António ^g   Araujo, Domingos ^g   Silva, Cândida ^h   Santos, Helena ^h   Duarte, Cátia ⁱ   Cáliz, Rafael ^j   Filipescu, Ileana ^k   Pimentel Santos, Fernando ^l,m   Branco, Jaime ^l,m   Sainz, Juan ⁿ   Plenge, Robert M ^c,o   Solomon, Daniel H ^c   Bruges Armas, Jácome ^e,f   Da Silva, José António P ⁱ   Fonseca, João Eurico ^a,b   Karlson, Elizabeth W ^c   more..

^a UNIVERSITY OF LISBON   (Portugal)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HOSPITAL GARCIA DE ORTA   (Portugal)

^e SEEBMO Hospital de Santo Espirito da Ilha Terceira Azores   (Portugal)

^f UNIVERSITY OF PORTO   (Portugal)

^g Rheumatology Department Conde de Bertiandos Hospital (ULSAM)   (Portugal)

^h INSTITUTO PORTUGUÊS DE REUMATOLOGIA   (Portugal)

ⁱ CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^k IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^l NOVA MEDICAL SCHOOL   (Portugal)

^m HOSPITAL EGAS MONIZ   (Portugal)

ⁿ UNIVERSITY OF GRANADA   (Spain)

^o BROAD INSTITUTE OF MIT AND HARVARD   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; CD45 ANTIGEN; HLA DRB1 ANTIGEN; MONOCLONAL ANTIBODY; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; PTPN22 PROTEIN, HUMAN; PTPRC PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; DNA EXTRACTION; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PORTUGUESE (CITIZEN); RHEUMATOID ARTHRITIS; SOUTHERN EUROPEAN; TREATMENT RESPONSE; AGED; ARTHRITIS, RHEUMATOID; GENETICS; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADALIMUMAB; ADULT; AGED; ALLELES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD45; ARTHRITIS, RHEUMATOID; ETANERCEPT; GENETIC ASSOCIATION STUDIES; HLA-DRB1 CHAINS; HUMANS; INFLIXIMAB; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; TNF RECEPTOR-ASSOCIATED FACTOR 1;

EID: 84925307951     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/490295     Document Type: Article

References (41)

1. P. C. Taylor and M. Feldmann, "Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis, " Nature Reviews Rheumatology, vol. 5, no. 10, pp. 578-582, 2009.
2. R. Maini, E. W. St Clair, F. Breedveld et al., "Infliximab (chimeric anti-tumour necrosis factor αmonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, "TheLancet, vol. 354, no. 9194, pp. 1932-1939, 1999.
3. I. B. McInnes and G. Schett, "The pathogenesis of rheumatoid arthritis, "The New England Journal ofMedicine, vol. 365, no. 23, pp. 2205-2219, 2011.
4. M. L. Hetland, I. J. Christensen, U. Tarp et al., "Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results fromeight years of surveillance of clinical practice in the nationwideDanishDANBIOregistry, " Arthritis and Rheumatism, vol. 62, no. 1, pp. 22-32, 2010.
5. K. L. Hyrich, K. D. Watson, A. J. Silman, and D. P. M. Symmons, "Predictors of response to anti-TNF-αtherapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register, " Rheumatology, vol. 45, no. 12, pp. 1558-1565, 2006.
6. H. Canhão, A. M. Rodrigues, A. F. Mourão et al., "Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis, " Rheumatology, vol. 51, no. 11, pp. 2020-2026, 2012.
7. L. Mancarella, F. Bobbio-Pallavicini, F. Ceccarelli et al., "Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-αblockers: the GISEA study, "The Journal of Rheumatology, vol. 34, no. 8, pp. 1670-1673, 2007.
8. D. Ligeiro, J. E. Fonseca, O. Abade et al., "Influence of human leucocyte antigen-DRB1 on the susceptibility to rheumatoid arthritis and on the production of anti-cyclic citrullinated peptide antibodies in a Portuguese population, " Annals of the Rheumatic Diseases, vol. 66, no. 2, pp. 246-248, 2007.
9. T. Barnetche, A. Constantin, A. Cantagrel, A. Cambon-Thomsen, and P.-A. Gourraud, "New classification of HLADRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samples, " Arthritis Research and Therapy, vol. 10, article R26, 2008.
10. A. W. Morgan, J. I. Robinson, P. G. Conaghan et al., "Evaluation of the rheumatoid arthritis susceptibility loci HLADRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort, " Arthritis Research and Therapy, vol. 12, no. 2, article R57, 2010.
11. J. A. B. Van Nies, R. B. Marques, S. Trompet et al., "TRAF1/C5 polymorphism is not associated with increased mortality in rheumatoid arthritis: two large longitudinal studies, " Arthritis Research andTherapy, vol. 12, no. 2, article R38, 2010.
12. V. F. Panoulas, J. P. Smith, P. Nightingale, and G. D. Kitas, "Association of the TRAF1/C5 locus with increased mortality, particularly from malignancy or sepsis, in patients with rheumatoid arthritis, " Arthritis and Rheumatism, vol. 60, no. 1, pp. 39-46, 2009.
13. J. R. O'Dell, B. S. Nepom, C. Haire et al., "HLA-DRB1 typing in rheumatoid arthritis: Predicting response to specific treatments, " Annals of the Rheumatic Diseases, vol. 57, no. 4, pp. 209-213, 1998.
14. G. Saruhan-Direskeneli, M. Inanc, I. Fresko et al., "The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis, " Rheumatology, vol. 46, no. 12, pp. 1842-1844, 2007.
15. L. A. Criswell, R. F. Lum, K. N. Turner et al., "The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept, " Arthritis and Rheumatism, vol. 50, no. 9, pp. 2750-2756, 2004.
16. A. Martinez, M. Salido, G. Bonilla et al., "Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients, "Arthritis and Rheumatism, vol. 50, no. 4, pp. 1077-1082, 2004.
17. J. E. Fonseca, T. Carvalho, M. Cruz et al., "Polymorphism at position-308 of the tumour factor αgene and rheumatoid arthritis pharmacogenetics, " Annals of the Rheumatic Diseases, vol. 64, no. 5, pp. 793-794, 2005.
18. S. Pavy, E. J. M. Toonen, C. Miceli-Richard et al., "Tumour necrosis factor-308GA polymorphism is not associated with response to TNFαblockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis, " Annals of the Rheumatic Diseases, vol. 69, no. 6, pp. 1022-1028, 2010.
19. M. Fabris, E. Di Poi, S. Sacco, G. Damante, L. Sinigaglia, and G. Ferraccioli, "TNF-αgene polymorphisms in rheumatoid arthritis patients treated with anti-TNF-αagents: preliminary results, " Reumatismo, vol. 54, no. 1, pp. 19-26, 2002.
20. L. Padyukov, J. Lampa, M. Heimbürger et al., "Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis, " Annals of the Rheumatic Diseases, vol. 62, no. 6, pp. 526-529, 2003.
21. R. M. Plenge, M. Seielstad, L. Padyukov et al., "TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study, " The New England Journal ofMedicine, vol. 357, no. 12, pp. 1199-1209, 2007.
22. E. A. Stahl, S. Raychaudhuri, E. F. Remmers et al., "Genomewide association study meta-analysis identifies seven new rheumatoid arthritis risk loci, " Nature Genetics, vol. 42, pp. 509-514, 2010.
23. P. R. Burton, D. G. Clayton, L. R. Cardon et al., "Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls, " Nature, vol. 447, no. 7145, pp. 661-678, 2007.
24. R. M. Plenge, L. Padyukov, E. F. Remmers et al., "Replication of putative candidate-gene associations with rheumatoid arthritis in <4, 000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4, " The American Journal of Human Genetics, vol. 77, no. 6, pp. 1044-1060, 2005.
25. A. Barton, W. Thomson, X. Ke et al., "Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility, " Human Molecular Genetics, vol. 17, no. 15, pp. 2274-2279, 2008.
26. W. Thomson, A. Barton, X. Ke et al., "Rheumatoid arthritis association at 6q23, " Nature Genetics, vol. 39, no. 12, pp. 1431-1433, 2007.
27. O. Snir, D. Gomez-Cabrero, A. Montes et al., "Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis, " Arthritis Research and Therapy, vol. 16, no. 5, article 414, 2014.
28. J. Varadé, R. Palomino-Morales, N. Ortego-Centeno et al., "Analysis of the rel polymorphism rs13031237 in autoimmune diseases, " Annals of the Rheumatic Diseases, vol. 70, no. 4, pp. 711-712, 2011.
29. J. Cui, S. Saevarsdottir, B. Thomson et al., "Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor αtherapy, " Arthritis and Rheumatism, vol. 62, no. 7, pp. 1849-1861, 2010.
30. C. Potter, K. L. Hyrich, A. Tracey et al., "Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis, " Annals of the Rheumatic Diseases, vol. 68, no. 1, pp. 69-74, 2009.
31. D. Plant, R. Prajapati, K. L. Hyrich et al., "Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort, " Arthritis and Rheumatism, vol. 64, no. 3, pp. 665-670, 2012.
32. H. Canhão, A. Faustino, F. Martins et al., "Reuma. pt: the rheumatic diseases portuguese register, " Acta Reumatologica Portuguesa, vol. 36, pp. 45-56, 2011
33. Biobanco-IMM, http://www.imm.fm.ul.pt/web/imm/biobank.
34. J. E. Fonseca, M. Bernardes, H. Canhão et al., "Portuguese guide lines for the use of biological agents in rheumatoid arthritis-october 2011 update, " Acta Reumatologica Portuguesa, vol. 36, no. 4, pp. 385-388, 2011.
35. F. C. Arnett, S. M. Edworthy, D. A. Bloch et al., "The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis, " Arthritis and Rheumatism, vol. 31, no. 3, pp. 315-324, 1988
36. DAS 28 calculator,/http://www.das-score.nl/das28/en.
37. A. M. van Gestel, M. L. L. Prevoo, M. A. van't Hof, M. H. van Rijswijk, L. B. A. van de Putte, and P. L. C. M. van Riel, "Development and validation of the European League against rheumatism response criteria for rheumatoid arthritis, " Arthritis and Rheumatism, vol. 39, no. 1, pp. 34-40, 1996.
38. F. A. Kurreeman, L. Padyukov, R. B. Marques et al., "A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis, " PLoS Medicine, vol. 4, no. 9, article e278, 2007.
39. M. Rothe, S. C. Wong, W. J. Henzel, and D. V. Goeddel, "A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor, " Cell, vol. 78, no. 4, pp. 681-692, 1994.
40. Y. Wang, J. Kristan, L. Hao, C. S. Lenkoski, Y. Shen, and L. A. Matis, "A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis, " Journal of Immunology, vol. 164, no. 8, pp. 4340-4347, 2000.
41. J. Cui, E. A. Stahl, S. Saevarsdottir et al., "Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis, " PLoS Genetics, vol. 9, no. 3, Article ID e1003394, 2013.